Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$15.38 USD
-0.07 (-0.45%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $15.40 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Teva Pharmaceutical Industries Ltd. has a PEG ratio of 0.86 compared to the Medical - Generic Drugs industry's PEG ratio of 3.29.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TEVA 15.38 -0.07(-0.45%)
Will TEVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Other News for TEVA
Teva management to meet with Truist
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2025 Earnings Call Highlights: Strong Growth in ...
Teva Pharmaceuticals (TEVA) Reports Continued Growth in Q2 2025
Truist Hosts Influential Meeting on July 30-31 with Focus on TEVA